Aileron Therapeutics Files DEFA14A for 2023 Annual Meeting Proxy

TL;DR

**ALRN filed proxy materials for its 2023 Annual Meeting, telling shareholders how to vote on key proposals.**

AI Summary

Aileron Therapeutics, Inc. (ALRN) has filed a DEFA14A, which is definitive additional proxy soliciting materials, for its 2023 Annual Meeting. This filing outlines how shareholders can vote online or by phone on various proposals, including the election of directors, the issuance of shares, and other corporate matters. This matters to shareholders because their votes will directly influence the company's governance and future strategic decisions, potentially impacting the value of their investment.

Why It Matters

Shareholders need to understand this filing to cast informed votes on critical company proposals, which will shape Aileron Therapeutics' future direction and potentially affect stock performance.

Risk Assessment

Risk Level: low — This filing is procedural, providing voting instructions for an upcoming annual meeting, and does not introduce new financial risks.

Analyst Insight

Investors should review the full proxy statement (which this DEFA14A supplements) to understand the specific proposals and make informed voting decisions for the 2023 Annual Meeting, as these votes impact company governance and strategy.

Key Players & Entities

• AILERON THERAPEUTICS INC (company) — the registrant filing the DEFA14A
• Board of Directors (company) — recommends votes on proposals
• 2023 Annual Meeting (date) — the event for which proxy materials are being distributed
• Washington, D.C. (location) — location of the SEC

FAQ

Filing Documents

• d575366ddefa14a.htm (DEFA14A) — 20KB
• g575366dsp002.jpg (GRAPHIC) — 292KB
• g575366dsp003.jpg (GRAPHIC) — 205KB
• g575366dsp004.jpg (GRAPHIC) — 171KB
• g575366dsp005.jpg (GRAPHIC) — 150KB
• 0001193125-24-020912.txt ( ) — 1140KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 2(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. MMMMMMMMMMMM MMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext ENDORSEMENT_LINE SACKPACK _ 000000000.000000 ext 000000000.000000 ext MR A SAMPLE DESIGNATION (IF ANY) ADD 1 Your vote matters heres how to vote! ADD 2 000001 You may vote online or by phone instead of mailing this card. ADD 3 ADD 4 MMMMMMMMM ADD 5 Online ADD 6 Go to www.envisionreports.com/ALRN or scan the QR code login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Using a black ink pen, mark your votes with an X as shown in this example. Sign up for electronic delivery at Please do not write outside the designated areas. www.envisionreports.com/ALRN 2023 Annual Meeting Proxy Card 1234 5678 9012 345 qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q A Proposals The Board of Directors recommends a vote FOR all the nominees listed, FOR Proposals 1, 3-5 and 7, and for 1 YEAR on Proposal 6 For Against Abstain 1. To Approve the Issuance, in Accordance with Nasdaq Listing Rule + 5635(a), of Our Common Stock, Upon Conversion of Our Outstanding Series X Non-Voting Convertible Preferred Stock. 2. Election of Three Class III Directors: 01Manuel C. Alves-Aivado, M.D., Ph.D. 02Reinhard Ambros, Ph.D. 03Josef H. von Rickenbach Mark here to vote FOR all nominees Mark here to WITHHOLD vote from all nominees 01 02 03 For All EXCEPTTo withhold a vote for one or more nominees, mark the box to the left and the corresponding numbered box(es) to the right. For Against Abstain For Against Abstain 3. To Approve an Amendment to the Aileron Therapeutics, Inc. 2021 Stock Incentive Plan to Increase the Number of Shares of 4. To Approve an Amendment to Our Restated Certificate of Our Common Stock Available for Issuance Thereunder by Incorporation, as Amended, to Increase the Number of 3,000,000 Shares. Authorized Shares of Our Common Stock from 45,000,000 to 100,000,000. 5. To Approve, on a Non-Binding, Advisory Basis, Our Named 1 Year 2 Years 3 Years Abstain Executive Officer Compensation. 6. To Approve, on a Non-Binding, Advisory Basis, the Frequency of Future Advisory Votes to Approve Our 7. Ratification of the Appointment of Marcum LLP as Our Named Executive Officer Compensation. Independent Registered Public Accounting Firm for the Fiscal Year ended December 31, 2023. B Authorized Signatures This section must be completed for your vote to count. Please date and sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) Please print date below. Signature 1 Please keep signature within the box. Signature 2 Please keep signature within the box. C 1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MMMMMM 1UPX 602433 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 03XLYC The 2023 Annual Meeting of Stockholders of Aileron Therapeutics, Inc. will be held on February 28, 2024 at 8:30 A.M. Eastern Standard Time, virtually via the internet at www.meetnow.global/MTD5ADS To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/ALRN qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q ProxyAileron Therapeutics, Inc. + Notice of 2023 Annual Meeting of Stockholders Proxy Solicited by Board of Directors for Annual Meeting February 28, 2024 Manuel C. Alves-Aivdao, M.D., Ph.D., Susan L. Drexler, Brian Windsor, Ph.D., and Charles Garner, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned,

View Full Filing

View this DEFA14A filing on SEC EDGAR